文献速递神经介入CT

硬膜外血补片术中纤维蛋白胶的超敏反应

Hypersensitivity Reactions to Fibrin Glue during Epidural Blood Patching.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-04-02

单中心回顾性队列(嵌套病例对照)纳入13年间1574例患者共3065次CT引导下纤维蛋白胶硬膜外血补片术,超敏反应发生率为每次操作0.49%、每例患者0.95%,且从未发生在首次使用纤维蛋白胶的硬膜外血补片术中;较低BMI、较年轻年龄及术中意外静脉注射与超敏反应风险升高相关。

要点

  • 纤维蛋白胶硬膜外血补片术超敏反应发生率低(每次操作0.49%、每例患者0.95%),且均未发生在首次使用纤维蛋白胶时。
  • 术中意外静脉注射与超敏反应风险升高相关(OR 5.44 [1.34-22.01],P = .014)。
  • 较低BMI(OR 0.82 [0.71-0.96],P = .003)和较年轻年龄(OR 0.95 [0.91-0.99],P = .011)与超敏反应风险升高相关。

核心结论

  • 纤维蛋白胶硬膜外血补片术中超敏反应发生率为0.49%,均未发生在首次暴露;较低BMI、较年轻年龄及术中意外静脉注射与反应可能性升高相关,本研究为告知患者操作风险提供数据并识别医生应知悉的变量以帮助预防危及生命的反应。

研究设计与样本

  • 单中心回顾性队列研究,嵌套病例对照设计,纳入13年间因医源性脑脊液漏或自发性颅内低压接受纤维蛋白胶硬膜外血补片术的患者,共1574例患者、3065次CT引导下操作,病例与对照按1:3匹配,采用logistic回归分析变量与超敏反应发生的关联。

诊断标准与关键数值

  • 超敏反应发生率:每次操作0.49%,每例患者0.95%。
  • 较低BMI与超敏反应风险升高相关(OR 0.82 [0.71-0.96],P = .003)。
  • 较年轻年龄与超敏反应风险升高相关(OR 0.95 [0.91-0.99],P = .011)。
  • 术中意外静脉注射与超敏反应风险升高相关(OR 5.44 [1.34-22.01],P = .014)。

临床应用与阅片要点

  • 作者指出本研究提供的数据可用于向患者告知操作风险。
  • 作者指出所识别的变量可供医生知悉,以帮助预防硬膜外血补片术中纤维蛋白胶引起的危及生命反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Fibrin glue is increasingly incorporated as a component in epidural blood patching (EBP) for the treatment of spinal CSF leaks. Hypersensitivity reactions are a potential complication of its use but are not well studied in the setting of EBP. The purpose of this study was to determine the incidence of hypersensitivity reactions to fibrin glue during EBP and to identify any predisposing factors associated with increased patient risk.

MATERIALS AND METHODS: A single-center retrospective cohort study with nested case-control design included patients who received fibrin glue EBP for the treatment of iatrogenic CSF leaks or spontaneous intracranial hypotension over 13 years. Patient demographics and multiple procedure-specific variables were collected. Cases were identified from the total cohort as those with hypersensitive reactions and matched with controls in a 1:3 ratio. The incidence of hypersensitivity reactions in the total cohort was calculated. Logistic regression models were fit to test for associations between variables and the development of a hypersensitivity reaction.

RESULTS: A total of 3065 CT-guided EBPs with fibrin glue were identified in 1574 individual patients. The incidence of hypersensitivity reactions was 0.49% per procedure and 0.95% per patient and never occurred during the first EBP with fibrin glue. Case-control analysis found higher odds for hypersensitivity reactions in patients with a lower BMI (OR 0.82 [0.71-0.96], P = .003), younger age (OR 0.95 [0.91-0.99], P = .011), and during procedures with inadvertent intravenous injections (OR 5.44 [1.34-22.01], P = .014).

CONCLUSIONS: We found a 0.49% incidence of hypersensitivity reactions during EBP with fibrin glue, none occurring during the first exposure. Younger age, lower BMI, and inadvertent intravenous injection during the procedure were associated with a higher likelihood of reactions. This study provides data useful for counseling patients on procedural risk and identifies variables for physicians to be aware of to help prevent life-threatening reactions to fibrin glue during EBP.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Smith JL, Kim MJ, Gray L, et al. Hypersensitivity Reactions to Fibrin Glue during Epidural Blood Patching. AJNR Am J Neuroradiol. 2025. PMID: 40113253. doi:10.3174/ajnr.A8568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。